Cell Biotech Co., Ltd. (KOSDAQ:049960)
South Korea
· Delayed Price · Currency is KRW 12,590
-60 (-0.47%)
At close: Mar 31, 2025, 3:30 PM KST
Cell Biotech Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Net Income | 15,127 | 6,304 | 8,281 | 10,383 | 3,189 | Upgrade
|
| Depreciation & Amortization | 3,872 | 3,904 | 3,638 | 3,789 | 3,685 | Upgrade
|
| Loss (Gain) From Sale of Assets | -10.14 | 82.45 | 0.91 | -29.05 | -9.48 | Upgrade
|
| Loss (Gain) From Sale of Investments | -575.56 | 211.19 | - | -111.68 | 50.69 | Upgrade
|
| Provision & Write-off of Bad Debts | 1.44 | -0.1 | -0.39 | -0.44 | 1.83 | Upgrade
|
| Other Operating Activities | 167.48 | -215.9 | 154.35 | 441.37 | 3,279 | Upgrade
|
| Change in Accounts Receivable | 817.31 | 51.01 | 39.38 | 144.48 | 10.32 | Upgrade
|
| Change in Inventory | -81.6 | -19.33 | -506.84 | -79.79 | -379.03 | Upgrade
|
| Change in Accounts Payable | 38.76 | -875.33 | 96.3 | 271.08 | -217.78 | Upgrade
|
| Change in Unearned Revenue | 0.54 | -3.86 | -19.54 | 8.92 | 10.33 | Upgrade
|
| Change in Income Taxes | - | -643.39 | - | - | - | Upgrade
|
| Change in Other Net Operating Assets | -90.03 | -979.12 | 1,131 | 74.98 | -55.21 | Upgrade
|
| Operating Cash Flow | 19,267 | 7,815 | 12,814 | 14,892 | 9,564 | Upgrade
|
| Operating Cash Flow Growth | 146.53% | -39.01% | -13.96% | 55.71% | -6.52% | Upgrade
|
| Capital Expenditures | -1,129 | -1,552 | -2,368 | -848.59 | -3,079 | Upgrade
|
| Sale of Property, Plant & Equipment | 79.5 | 0 | 1.7 | 16.77 | 11.05 | Upgrade
|
| Sale (Purchase) of Intangibles | -113.83 | -123.92 | -304.2 | 25.86 | -13.8 | Upgrade
|
| Investment in Securities | -17,685 | -3,062 | -4,138 | -10,499 | 1,511 | Upgrade
|
| Other Investing Activities | 213.05 | 12.17 | 38.62 | 2.6 | 112.42 | Upgrade
|
| Investing Cash Flow | -18,737 | -4,745 | -6,669 | -11,132 | -1,627 | Upgrade
|
| Long-Term Debt Repaid | -661.5 | -641.07 | -636.49 | -676.15 | -668.04 | Upgrade
|
| Net Debt Issued (Repaid) | -661.5 | -641.07 | -636.49 | -676.15 | -668.04 | Upgrade
|
| Repurchase of Common Stock | - | - | -3,719 | - | -2,607 | Upgrade
|
| Dividends Paid | -3,080 | -3,080 | -3,182 | -3,182 | -4,341 | Upgrade
|
| Financing Cash Flow | -3,741 | -3,721 | -7,538 | -3,858 | -7,616 | Upgrade
|
| Foreign Exchange Rate Adjustments | 83.65 | 76.91 | -9.33 | 357.88 | -144.49 | Upgrade
|
| Miscellaneous Cash Flow Adjustments | - | 0 | -0 | - | - | Upgrade
|
| Net Cash Flow | -3,128 | -573.48 | -1,402 | 260.35 | 177.19 | Upgrade
|
| Free Cash Flow | 18,138 | 6,264 | 10,445 | 14,044 | 6,485 | Upgrade
|
| Free Cash Flow Growth | 189.57% | -40.03% | -25.62% | 116.55% | 749.73% | Upgrade
|
| Free Cash Flow Margin | 36.34% | 11.65% | 20.67% | 29.96% | 14.23% | Upgrade
|
| Free Cash Flow Per Share | 2649.95 | 915.17 | 1515.03 | 1985.94 | 914.17 | Upgrade
|
| Cash Interest Paid | 60.88 | 61.95 | 37.49 | 42.48 | 39.08 | Upgrade
|
| Cash Income Tax Paid | -1,539 | 1,355 | 1,371 | -136.75 | -500.6 | Upgrade
|
| Levered Free Cash Flow | 9,753 | -335.57 | 5,547 | 9,207 | 3,057 | Upgrade
|
| Unlevered Free Cash Flow | 9,791 | -296.85 | 5,571 | 9,233 | 3,088 | Upgrade
|
| Change in Net Working Capital | -2,914 | 3,898 | -823.65 | -1,731 | -203.87 | Upgrade
|
Updated Nov 14, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.